WuXi Biologics and Fresenius agreed to a large biosimilar manufacturing partnership covering up to 37 assets, positioning the companies ahead of what parts of the industry describe as a coming “golden decade” for biosimilars. The deal points to a continued shift toward scaling production capacity early—particularly as patent expirations and biosimilar launches increase the demand for contract manufacturing and late-stage development infrastructure. For biotech executives and planners, the structure of such broad deals signals how supply-chain commitments may be used to secure position across multiple molecules rather than single-asset programs.